Q-omics provides the consensus-scored LINC01602 profile across patient tissues and cancer cell-line models. LINC01602 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, LINC01602 is differentially expressed in 7, with the highest sampling consensus in COAD. Additionally, LINC01602 RNA expression shows 5,504 significant pathway-activity associations, with the highest sampling consensus in UCEC. Together, these results highlight COAD, and UCEC as cancer lineages where LINC01602 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01602 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01602 survival associations across molecular data types. LINC01602 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01602 RNA expression–survival associations across cancer types. High LINC01602 expression shows unfavorable associations in COAD, KIRP, KICH, CHOL and UCEC, but favorable associations in LGG. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for LINC01602 RNA expression.
This table summarizes LINC01602 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01602. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01602 shows lower tumor expression in LUAD and higher tumor expression in COAD, HNSC, STAD, BRCA and LUSC. The COAD box plot shows higher LINC01602 RNA expression in tumor versus normal tissue (log2 FC = +0.408, t-test p < 0.001).
This table shows molecular features associated with LINC01602 in patient tissues and cancer cell lines. In patient samples, LINC01602 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set. In cancer cell lines, LINC01602 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC.
